Cybin Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
6.92
+0.29 (4.37%)
Jul 10, 2026, 3:45 PM EDT - Market open
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
428.93M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Vanda Pharmaceuticals | 217.78M |
| Foghorn Therapeutics | 28.22M |
| Abeona Therapeutics | 14.54M |
| X4 Pharmaceuticals | 9.01M |
| Adlai Nortye | 5.00M |
| Lyell Immunopharma | 31.00K |
HELP News
- 1 day ago - Psychedelic: Compass Pathways reports six-month data for psilocybin drug - TheFly
- 1 day ago - Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright - TheFly
- 9 days ago - Helus Pharma price target lowered to $42 from $45 at Canaccord - TheFly
- 11 days ago - Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results - GlobeNewsWire
- 11 days ago - Cybin Annual report: Q4 2026 - Filings
- 11 days ago - Cybin Earnings release: Q4 2026 - Filings
- 11 days ago - Cybin Slides: Corporate presentation - Filings
- 15 days ago - Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering - GlobeNewsWire